Covaxin demonstrates robust safety and immunogenicity in 2-to-18-year-old volunteers : Study

COVAXIN one of the first COVID-19 vaccines in 2 to 18 year age group has showcased well-tolerated and immunogenic in paediatric subjects, informs phase II/III, open-label, multi-centre study.

from Top Health News | Latest Health & Healthcare Industry Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/31gSaMg